RightFit
RecruitingNot applicable

Access to Genetic Testing in Underserved Patients With Cancer

Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Interviews

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "USABILITY PHASE: Participants attend usability testing and provide feedback through cognitive interviews."
  • "PILOT TESTING PHASE: Participants evaluate the newly developed PERLAs and provide feedback through focused interviews and structured assessment."
  • "IMPLEMENTATION PHASE: Participants complete qualitative interviews to evaluate potential barriers and facilitators to implementation of PERLA in the clinic."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares learning about genetic testing from a computer-created character with learning from a human genetics care provider. Genetic testing looks for changes in genes. The study is for adults with certain cancers and providers who treat them, with a focus on people who have limited access to genetic services.

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You must be older than 18.
  • You must have one of the cancers listed below, or be a healthcare provider who treats people with one of them.
  • Epithelial ovarian cancer (cancer in cells covering the ovary) or exocrine pancreatic cancer (cancer in cells that make digestive juices).
  • Prostate cancer that has spread, or is rated high risk or very high risk.
  • Breast cancer diagnosed at age 50 or younger, or cancer in both breasts.
  • Triple-negative breast cancer (cancer without three common cell markers), or breast cancer in a man.
  • You must be able to read and write in English or Spanish.
  • You must be able to give informed consent, meaning you understand the study and agree to join.

Who can't join

  • Patients who cannot understand the study and agree to join.
  • Patients who cannot see, read, or write.
  • Patients who do not speak English or Spanish.
  • Patients who do not have any of the listed cancer types and features.
  • Healthcare providers who do not treat people with cancer.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age \> 18 years old * Diagnosed with least one of the following: * Epithelial ovarian cancer * Exocrine pancreatic cancer * Metastatic or high or very high-risk prostate cancer * Breast cancer at or before age 50 * Bilateral breast cancer * Triple negative breast cancer * Male breast cancer OR * Healthcare provider who treats patients with any of the above types of cancer * Able to read and write in English or Spanish * Able to provide informed consent Exclusion Criteria: * Patients who cannot provide informed consent * Patients who cannot see, read, or write * Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish * Patients with none of the listed cancer diagnoses and clinical characteristics * Healthcare provider who do not treats cancer patients

Study sites (2)

CA

NY